Heparan sulfate-based treatments for regenerative medicine

Critical Reviews in Eukaryotic Gene Expression

Volumn 21, Issue 1, 2011, Pages 1-12

  Rai, Bina ^a   Nurcombe, Victor ^a,b   Cool, Simon M ^a,b  

^a INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bone; Delivery; Growth factor; Heparan sulfate

Indexed keywords

ALKALINE PHOSPHATASE; BIOMATERIAL; BONE MORPHOGENETIC PROTEIN 2; COLLAGEN; COLLAGEN TYPE 1; FIBRIN GLUE; FIBROBLAST GROWTH FACTOR; GELATIN; HEPARAN SULFATE; HEPARIN; HYDROXYAPATITE; MACROGOL; NANOFILM; NANOSPHERE; OSTEOCALCIN; OSTEOPONTIN; PERLECAN; POLYMER; POLYVINYL ALCOHOL; REGENERATING AGENT; TISSUE SCAFFOLD; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; WATER OIL CREAM;

BONE DEFECT; BONE REMODELING; CELL DIFFERENTIATION; DRUG DELIVERY SYSTEM; ENCAPSULATION; HUMAN; HYDROGEL; MESENCHYMAL STEM CELL; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE;

EID: 80052072427     PISSN: 10454403     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevEukarGeneExpr.v21.i1.10     Document Type: Review

References (92)

1. Baylink DJ, Finkelman RD, Mohan SE. Growth factors to stimulate bone formation. J Bone Miner Res. 1993;8:S565-72.
2. Canalis E. Skeletal growth factors. In: Marcus R, Feldman D, Kelsey J, editors. Osteoporosis. San Diego: Academic Press; 1996. p. 261-79.
3. Beck SL, Deguzman L, Lee WP, Xu Y, McFatridge A, Gillett NA, Amento EP. IGF-β1 induces bone closure of skull defects. J Bone Miner Res. 1991;11:1257-65.
4. Marden L, Hollinger JO, Chaudhari A, Turek T, Schaub RG, Ron E. Recombinant human bone morphogenetic protein-2 is superior to demineralized bone matrix in repairing craniotomy defects in rats. J Biomed Mater Res. 1994;28:1127-38.
5. Jingushi S, Heydemann A, Kana SK, Macey LR, Bolander ME. Acidic fibroblast growth factor injection stimulates cartilage enlargement and inhibits cartilage gene expression in rat fracture healing. J Orthop Res. 1990;8:364-71.
6. Lind M, Schumacker B, Soballe K, Keller J, Melsen F, Bunger C. Transforming growth factor-β enhances fracture healing in rabbit tibiae. Acta Orthop Scand. 1993;64:553-6.
7. Kawaguchi H, Kurokawa T, Hanada K, Hiyama Y, Tamura M, Ogata E, Matsumoto T. Stimulation of fracture repair by recombinant human basic fibroblast growth factor in normal and streptozotocin-diabetic rats. Endocrinology. 1994;135:774-81.
8. Cook SD, Baffes GC, Wolfe MW, Sampath TK, Rueger DC. Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model. Clin Orthop Rel Res. 1994;301:302-12.
9. Yasko AW, Lane JM, Fellinger EJ. The healing of segmental bone defects induced by recombinant human bone morphogenetic protein (rhBMP-2). J Bone Joint Surg. 1992; 74:659-70.
10. Marden LJ, Fan RS, Pierce GF, Reddi AH, Hollinger JO. Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects. J Clin Invest. 1993;92:2897-905.
11. Blanquaert F, Barritault D, Caruelle JP. Effects of heparan-like polymers associated with growth factors on osteoblast proliferation and phenotype expression. J Biomed Mater Res. 1999;44:63-72.
12. Nurcombe V, Kumarasuriyar A, Cool SM. The development of heparan sulfate sugars as therapeutics: versatility that couples stem cells, tissue engineering and wound repair. Drug Dev Res. 2004;62:303-16.
13. Cool SM, Nurcombe V. The osteoblast-heparan sulfate axis: control of the bone cell lineage. Int J Biochem Cell Biol. 2005;37:1739-45.
14. Jenniskens GJ, Veerkamp JH, van Kuppevelt TH. Heparan sulfates in skeletal muscle development and physiology. J Cell Physiol. 2006;206:283-94.
15. Bishop JR, Schuksz M, Esko JD. Heparan sulfate proteoglycans fine-tune mammalian physiology. Nature. 2007;446:1030-7.
16. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol. 1998;107:743-51.
17. Ruoslathi E, Yamaguchi D. Proteoglycans as modulators of growth factor activities. Cell. 1991;64:867-9.
18. Presta M, Maier JA, Rusnati M, Ragnotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol. 1989;140:68-74.
19. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of transforming growth factor-β1 activity by heparin and fucoidan. J Cell Physiol. 1994; 159:51-9.
20. Jackson RA, Murali S, van Wijnen AJ, Stein GS, Nurcombe V, Cool SM. Heparan sulfate regulates the anabolic activity of MC3T3-E1 preosteoblast cells by induction of Runx2. J Cell Physiol. 2007;210:38-50.
21. Ling L, Murali S, Stein GS, van Wijnen AJ, Cool SM. Glycosaminoglycans modulate RANKL-induced osteoclastogenesis. J Cell Biochem. 2010;109:1222-31.
22. Song SJ, Hutmacher DW, Nurcombe V, Cool SM. Temporal expression of proteoglycans in the rat limb during bone healing. Gene. 2006;379:92-100.
23. Jackson RA, McDonald MM, Nurcombe V, Little DG, Cool SM. The use of heparan sulfate to augment fracture repair in rat fracture model. J Orthop Res. 2006;24:636-44.
24. Amanat N, Brown R, Bilston LE, Little DG. A single systemic dose of pamidronate improves bone mineral content and accelerates restoration of strength in a rat model of fracture repair. J Orthop Res. 2005;23:1029-34.
25. Nurcombe V, Ford MD, Wildschut JA, Bartlett PF. Developmental regulation of neural response to Fgf-1 and Fgf-2 by heparan sulfate proteoglycan. Science. 1993;260:103-6.
26. Litwack ED, Ivins JK, Kumbasar A, Saunders SP, Stipp CS, Lander AD. Expression of the heparan sulfate proteoglycan glypican-1 in the developing rodent. Dev Dyn. 1998;211:72-87.
27. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev. 1996;15:177-86.
28. Woodruff MA, Rath SN, Susanto E, Haupt LM, Hutmacher DW, Nurcombe V, Cool SM. Sustained release and osteogenic potential of heparan sulfate-doped fibrin glue scaffolds within a rat cranial model. J Mol Histol. 2007;38:425-33.
29. DeBlois C, Cote MF, Doillon CJ. Heparin-fibroblast growth factor fibrin complex: in vitro and in vivo applications to collagen based materials. Biomaterials. 1994;15:665-72.
30. Pandit AS, Wilson DJ, Feldman DS. Fibrin scaffold as an effective vehicle for the delivery of acidic fibroblast growth factor (FGF-1). J Biomater Appl. 2000;14:229-42.
31. Rai B, Teoh SH, Hutmacher DW, Cao T, Ho KH. Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2. Biomaterials. 2005;26:3739-48.
32. Jackson RA, Nurcombe V, Cool SM. Coordinated fibroblast growth factor and heparan sulfate regulation of osteogenesis. Gene. 2006;379:79-91.
33. Jaeger R, Bergshoef MM, Batlle CMI, Schonherr H, Vansco GJ. Electrospinning of ultra-thin polymer fibers. Macromol Symp. 1998;127:141-50.
34. Li D, Xia Y. Electrospinning of nanofibers: reinventing the wheel? Adv. Mater. 2004;16:1151-70.
35. Boudriot U, Dersch R, Greiner A, Wendorff JH. Electrospinning approaches toward scaffold engineering - a brief overview. Artif Organs. 2006;30:785-92.
36. Edelman ER, Adams DH, Karnovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci USA. 1990;87:3773-7.
37. Rogers C, Karnovsky MJ, Edelman ER. Inhibition of experimental neointimal hyperplasia and thrombosis on the type of vascular injury and the site of drug administration. Circulation. 1993;88:1215-21.
38. Edelman ER, Nathan A, Katada M, Gates J, Karnovsky MJ. Perivascular graft heparin delivery using biodegradable polymer wraps. Biomaterials. 2000;21:2279-86.
39. Luong-Van E, Grondahl L, Chua KN, Leong KW, Nurcombe V, Cool S. Controlled release of heparin from poly (ε-caprolactone) electrospun fibers. Biomaterials. 2006;27:2042-50.
40. Luong-Van E, Grondahl L, Song SJ, Nurcombe V, Cool S. The in vivo assessment of a novel scaffold containing heparan sulfate for tissue engineering with human mesenchymal stem cells. J Mol Histol. 2007;38:459-68.
41. Brickman YG, Ford MD, Gallagher JT, Nurcombe V, Bartlett PF, Turnbull JE. Structural modification of fibroblast growth factor-binding heparan sulfate at a determinative stage of neural development. J Biol Chem. 1998;273:4350-9.
42. Vos JG, Berkvens JM, Kruijt BC. The athymic nude rat. I. Morphology of lymphoid and endocrine organs. Clin Immunol Immunopathol. 1980;15:213-28.
43. van Luyn MJ, Khouw IM, van Wachem PB, Blaauw EH, Werkmeister JA. Modulation of the tissue reaction to biomaterials. II. The function of T cells in the inflammatory reaction to crosslinked collagen implanted in T-cell-deficient rats. J Biomed Mater Res. 1998;39:398-406.
44. Xia Z, Taylor PR, Locklin RM, Gordon S, Cui Z, Triffitt JT. Innate immune response to human bone marrow fibroblastic cell implantation in CB17 scid/beige mice. J Cell Biochem. 2006;98:966-80.
45. Ekaptura AK, Prestwich G, Cool SM, Hutmacher DW. Combining electrospun scaffolds with electrosprayed hydrogels leads to three-dimensional cellularisation of hybrid constructs. Biomacromolecules. 2008;9:2097-103.
46. Luong-Van E, Grondahl L, Nurcombe V, Cool S. In vitro biocompatibility and bioactivity of microencapsulated heparan sulfate. Biomaterials. 2007;28:2127-36.
47. Reddi AH. BMPs: from bone morphogenetic proteins to body morphogenetic proteins. Cytokine Growth Factor Rev. 2005;16:249-50.
48. Deschaseaux F, Sensebe L, Heymann D. Mechanisms of bone repair and regeneration. Trends Mol Med. 2009;15:417-29.
49. Benoit DSW, Collins SD, Anseth KS. Multifunctional hydrogels that promote osteogenic hMSC differentiation through stimulation and sequestering of BMP2. Adv Funct Mater. 2007;17:2085-93.
50. Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa K, Ogama A, Kamijo RJ. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. Biol Chem. 2003;278:43229-35.
51. Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, Franceschi RT. Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res. 2002;17:101-10.
52. Jeon O, Song SJ, Kang SW, Putnam AJ, Kim BS. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(L-lactic-co-glycolic acid) scaffold. Biomaterials. 2007;28:2763-71.
53. Zhao B, Katagiri T, Toyoda H, Takada T, Yanai T, Fukuda T, Chung UI, Koike T, Takaoka K, Kamijo R. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem. 2006;281:23246-53.
54. Liu L, Ng C, Thompson AY, Poser JW, Spiro RC. Hyaluronate- heparin conjugate gels for the delivery of basic fibroblast growth factor (FGF-2). J Biomed Mater Res. 2002;62:128-35.
55. Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G, Cohen S. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A. 2003;65:489-97.
56. Jeon O, Ryu SH, Chung JH, Kim BS. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J Control Release. 2005;105:249-59.
57. Han D, Liu W, Ao Q, Wang G. Optimal delivery systems for bone morphogenetic proteins in orthopedic applications should model initial tissue repair structures by using a heparin-incorporated fibrin-fibronectin matrix. Med Hypotheses. 2008;71:374-8.
58. Jeon O, Song SJ, Yang HS, Bhang SH, Kang SW, Sung MA, Lee JH, Kim BS. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. Biochem Biophy Res Commun. 2008;369:774-80.
59. Yang HS, La WG, Bhang SH, Jeong-Yi J, Lee JH, Kim BS. Heparin-conjugated fibrin as an injectable system for sustained delivery of bone morphogenetic protein-2. Tissue Eng Part A. 2010;16:1225-33.
60. Teixeira S, Yang L, Dijkstra PJ, Ferraz MP, Monteiro FJ. Heparinized hydroxyapatite/collagen three-dimensional scaffolds for tissue engineering. J Mater Sci Mater Med. 2010;21:2385-92.
61. Crouzier T, Szarpak A, Boudou T, Auzely-Velty R, Picart C. Polysaccharide-blend multilayers containing hyaluronan and heparin as a delivery system for rhBMP-2. Small. 2010;6:651-62.
62. Meddahi A, Blanquaert F, Saffar JL, Colombier ML, Caruelle JP, Josefonvicz J, Barritault D. New approaches to tissue regeneration and repair. Pathol Res Pract. 1994; 190:923-8.
63. Gautron J, Kedzia C, Husmann I, Barritault D. Acceleration of the regeneration of skeletal muscles in adult rats by dextran derivatives. CR Acad Sci-III Vie. 1995;318:671-6.
64. Meddahi A, Benoit J, Ayoub N, Sezeur A, Barritault D. Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage. J Biomed Mater Res. 1996;31:293-7.
65. Lafont J, Baroukh B, Meddahi A, Caruelle JP, Barritault D, Saffar JL. Derivative dextrans (CMDBS) as promoters of bone healing. Factors influencing their effectiveness. Cell Mater. 1994;4:219-30.
66. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparan-like molecules induce the repair of skull defects. Bone. 1995;17:499-506.
67. Albo D, Long C, Jhala N, Atkinson B, Granick MS, Want T, Meddahi A, Barritault D, Solomon MP. Modulation of cranial bone healing with a heparin-like dextran derivative. J Craniofac Surg. 1996;7:19-22.
68. Tardieu M, Slaoui F, Josefonvicz J, Courty J, Gamby C, Barritault D. Biological and binding studies of acidic fibroblast growth factor in the presence of substituted dextran. J Biomater Sci Polymer Ed. 1989;1:63-70.
69. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol. 1988;107:743-51.
70. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth W. Protection of transforming growth factor-β1 activity by heparin and fucoidan. J Cell Physiol. 1994;159:51-9.
71. Ruoslathi E, Yamaguchi D. Proteoglycans as modulators of growth factor activities. Cell. 1991;64:867-9.
72. Presta M, Maier JA, Rusnati M, Ragnotti G. Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J Cell Physiol. 1989;140:68-74.
73. Tardieu M, Gamby C, Avramoglou T, Josefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol. 1992;150:194-203.
74. McCaffrey TA, Falcone DJ, Brayton CF, Agarwal LA, Welt FGP, Weksler BB. Transforming growth factor-β activity is potentiated by heparin via dissociation of the transforming growth factor-β/α2-macroglobulin inactive complex. J Cell Biol. 1989;109:441-8.
75. Sommer A, Rifkin DB. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol. 1989;138:215-20.
76. Flaumenhaft R, Moscatelli D, Sommer A, Rifkin DB. Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for longterm stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol. 1988;140:75-81.
77. Lafont J, Blanquaert F, Colombier ML, Barritault D, Caruelle JP, Saffar JL. Kinetic study of early regenerative effects of RGTA11, a heparan sulfate mimetic, in rat craniotomy defects. Calcif Tissue Int. 2004;75:517-25.
78. Escartin Q, Lallam-Laroye C, Baroukh B, Morvan FO, Caruelle JP, Godeau G, Barritault D, Saffar JL. A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers. FASEB J. 2003;17:644-51.
79. Murdoch AD, Dodge GR, Cohen I, Tuan RS, Iozzo RV. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan): a chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J Biol Chem. 1992;267:8544-57.
80. Carson DD, Tang J-P, Julian J. Heparan sulfate proteoglycan (perlecan) expression by mouse embryos during acquisition of attachment competence. Dev Biol. 1993;155:97-106.
81. Murdoch AD, Liu B, Schwarting R, Tuan RS, Iozzo RV. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J Histochem Cytochem. 1994;42:239-49.
82. Arikawa-Hirasawa E, Wilcox WR, Yamada Y. Dyssegmental dysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage development. Am J Med Genet. 2001;106:254-7.
83. Melrose J, Smith S, Knox S, Whitelock J. Perlecan, the multidomain HS-proteoglycan of basement membranes is a prominent pericellular component of ovine hypertrophic vertebral growth plate and cartilaginous endplate chondrocytes. Histochem Cell Biol. 2002;118:269-80.
84. Aszodi A, Bateman JF, Gustafsson E, Boot-Handford R, Fassler R. Mammalian skeletogenesis and extracellular matrix: what can we learn from knockout mice? Cell Struct Funct. 2000;25:73-84
85. Nicole S, Davoine CS, Topaloglu H, Cattolico L, Barral D, Beighton P, Hamida CB, Hammouda H, Cruaund C, White PS, Samson D, Urtizberea JA, Lehmann-Horn F, Weissenbach J, Hentati F, Fontaine B. Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet. 2000;26:480-3.
86. DeCarlo AA, Whitelock JM. The role of heparan sulfate and perlecan in bone regenerative procedures. J Dent Res. 2006;85:122-32.
87. Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa K, Ogamo A, Kamijo R. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem. 2003;278:43229-35.
88. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem. 1996;237:295-302.
89. Jha AK, Yang W, Kirn-Safran CB, Farach-Carson MC, Jia X. Perlecan domain 1-conjugated hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials. 2009;30:6964-75.
90. Knudson CB, Knudson W. Cartilage proteoglycans. Sem Cell Dev Biol. 2001;12:69-78.
91. Hegewald AA, Ringe J, Bartel J, Kruger I, Notter M, Barnewitz D, Kaps C, Sittinger M. Hyaluronic acid and autologous synovial fluid induce chondrogenic differentiation of equine mesenchymal stem cells: a preliminary study. Tissue Cell. 2004;36:431-8.
92. Knudson W, Loeser RF. CD44 and integrin matrix receptors participate in cartilage homeostasis. Cell Mol Life Sci. 2002;59:36-44.